NCT05807542View on ClinicalTrials.gov

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

April 30, 2024

Conditions
Esophagus Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.

DRUG

Paclitaxel-albumin

Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.

DRUG

Carboplatin

carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.

Trial Locations (1)

361000

ShanghaiZhongshan, Xiamen

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER